Hormone Receptor-positive Breast Cancer
📧 Sign up to get email alerts when something new happens for Hormone Receptor-positive Breast Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-02-09Clinical Trial Update: Study of Screening Brain MRIs in Stage IV Breast Cancer
A clinical trial at H. Lee Moffitt Cancer Center is evaluating the use of screening brain MRIs in patients with Stage IV breast cancer, incl…
-
CLINICAL_TRIALS trial_result · 2026-02-06Clinical Trial Update: A Study of Revaree Plus in People With Breast Cancer [Phase 4]
Phase 4 clinical trial update for Revaree Plus in breast cancer patients is currently recruiting.
-
CLINICAL_TRIALS research · 2026-02-06Clinical Trial Update: DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Metastatic Breast Cancer Patients
DiviTum TKa is being evaluated as a biomarker assay in a clinical trial for efficacy in HR-positive, HER2-negative metastatic breast cancer;…
-
CLINICAL_TRIALS research · 2026-02-06Clinical Trial Update: A Phase III Clinical Trial of NTQ1062 in Combination With Fulvestrant for the Treatment of Advanced or Metastatic HR+/HER2- Breast Cancer [Phase 3]
A Phase III trial evaluating NTQ1062 in combination with Fulvestrant for advanced or metastatic hormone receptor-positive/HER2-negative brea…
-
CLINICAL_TRIALS research · 2026-02-05Clinical Trial Update: Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2) [Phase 3]
A Phase 3 trial (VIKTORIA-2) is evaluating Gedatolisib as first-line therapy for HR-positive, HER2-negative advanced breast cancer and is cu…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-01-30Clinical Trial Update: Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer [Phase 3]
A Phase 3 trial update reports on neoadjuvant Pyrotinib for hormone-receptor-positive, HER2-low high-risk early breast cancer, with the tria…
-
CLINICAL_TRIALS research · 2026-01-29Clinical Trial Update: Acutherapy to Prevent Aromatase Inhibitor-Associated Arthralgias in Non-Hispanic Black Postmenopausal Women With Early-Stage Breast Cancer [NA]
This ClinicalTrials.gov entry indicates a study sponsored by Emory University to test Acutherapy for preventing aromatase inhibitor–associat…
-
CLINICAL_TRIALS trial_result · 2026-01-28Clinical Trial Update: Study of Sacituzumab Govitecan With Atropine to Improve Tolerability in Advanced TNBC and HR+/HER2- Breast Cancer [Phase 2]
A Phase 2 clinical trial evaluating sacituzumab govitecan in combination with atropine to improve tolerability in advanced breast cancers, i…
-
CLINICAL_TRIALS research · 2026-01-26Clinical Trial Update: CDK4/6 Inhibitors Combined With Endocrine Therapy for Neoadjuvant Treatment [Phase 2]
A Phase 2 neoadjuvant trial is evaluating CDK4/6 inhibitors combined with endocrine therapy for hormone receptor-positive breast cancer; the…
-
CLINICAL_TRIALS trial_result · 2026-01-22Clinical Trial Update: Pembrolizumab in Treating Patients With Hormone Receptor Positive, Localized Inflammatory Breast Cancer Who Are Receiving Hormone Therapy and Did Not Achieve a Pathological Complete Response to Chemotherapy [Phase 2]
Phase 2 trial evaluating pembrolizumab in hormone receptor-positive, localized inflammatory breast cancer patients on hormone therapy who di…
-
CLINICAL_TRIALS research · 2026-01-20Clinical Trial Update: Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 [Phase 1]
Phase 1 study assessing adverse events and change in disease activity in adults with select advanced solid tumors treated with ABBV-400; the…
-
CLINICAL_TRIALS research · 2026-01-12Clinical Trial Update: A Study of Olaparib and Pembrolizumab in People With Triple Negative Breast Cancer (TNBC) or Hormone Receptor-positive HER2-negative Breast Cancer [Phase 2]
Phase 2 trial evaluating the combination of olaparib and pembrolizumab in triple-negative breast cancer and hormone receptor-positive, HER2-…
-
CLINICAL_TRIALS research · 2026-01-06Clinical Trial Update: RWE About QOL and Compliance of Patients With OFS in China
A completed clinical trial provides real-world evidence on quality of life and adherence among patients treated with ovarian function suppre…
-
CLINICAL_TRIALS trial_result · 2026-01-02Clinical Trial Update: Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer [Phase 2]
Phase 2 trial evaluating alpelisib in combination with continued endocrine therapy after progression in HR-positive, HER2-negative, PIK3CA-m…
-
CLINICAL_TRIALS research · 2025-12-18Clinical Trial Update: Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer
This ClinicalTrials.gov entry describes a prospective registry evaluating an antibody-drug conjugate as first- and second-line therapy for b…
-
CLINICAL_TRIALS research · 2025-12-05Clinical Trial Update: Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer [Phase 3]
A Phase 3 clinical trial evaluating SKB264 for locally advanced, recurrent or metastatic HR+/HER2- breast cancer is currently recruiting.
-
CLINICAL_TRIALS research · 2025-12-05Clinical Trial Update: A Prospective NIS to Evaluate the Clinical Outcomes of Risarg® (Ribociclib) Combined With Endocrine Therapy or Chemotherapy in Patients With HR+HER2 - aBC in Routine Clinical Practice in the Russia
A prospective non-interventional study in Russia evaluates clinical outcomes of Ribociclib (Risarg) combined with endocrine therapy or chemo…
-
CLINICAL_TRIALS other · 2025-12-05Clinical Trial Update: Clinical Study to Evaluate Debio0123 + Sacituzumab Govitecan Combination in TNBC or HR+/HER2- Advanced Breast Cancer [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating Debio0123 in combination with sacituzumab govitecan for advanced breast cancer (TNBC or HR+/HER2-); stud…
-
CLINICAL_TRIALS trial_result · 2025-12-04Clinical Trial Update: Preventive stRategy for IMMU132-relatED AEs in TNBC or Luminal Breast Cancer- PRIMED [Phase 2]
A Phase 2 trial (PRIMED) evaluating a preventive strategy for IMMU132-related adverse events in triple-negative and HR+/HER2-negative breast…
-
CLINICAL_TRIALS research · 2025-11-17Clinical Trial Update: SKB264 +/- KL-A167 in Recurrent or Metastatic HER2-negative Breast Cancer [Phase 2]
Phase 2 study updating SKB264 with or without KL-A167 for recurrent/metastatic HER2-negative breast cancer, including triple-negative and HR…
-
CLINICAL_TRIALS other · 2025-11-13Clinical Trial Update: A Ph II Study of the TheraBionic P1 Device in Subjects With Hormone Positive Breast Cancer [NA]
Update on a Phase II study of the TheraBionic P1 Device for hormone receptor-positive, HER2-negative breast cancer, with recruitment not yet…
-
CLINICAL_TRIALS research · 2025-11-10Clinical Trial Update: Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer [Phase 2]
A Phase 2 clinical trial evaluating trastuzumab deruxtecan, alone or in combination with anastrozole, for early-stage HER2-low, hormone rece…
-
CLINICAL_TRIALS research · 2025-11-10Clinical Trial Update: BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer [Phase 1]
BeOne Medicines is conducting a Phase 1 trial evaluating BGB-21447, a Bcl-2 inhibitor, in combination regimens for adults with hormone recep…
-
CLINICAL_TRIALS trial_result · 2025-10-31Clinical Trial Update: Breast Cancer Survivors Who Experience Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS)
A clinical trial evaluating aromatase inhibitor-associated musculoskeletal symptoms in breast cancer survivors has completed.
-
FDA approval · 2025-10-30FDA Approved: EVEROLIMUS — Original Application (Novugen Pharma (USA) LLC.)
FDA approved a generic version of Everolimus from Novugen Pharma (USA) LLC under an Original Application (ANDA).